<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01042730</url>
  </required_header>
  <id_info>
    <org_study_id>CSP-LD-09</org_study_id>
    <nct_id>NCT01042730</nct_id>
  </id_info>
  <brief_title>Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease (REAL-CAD)</brief_title>
  <official_title>Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease (REAL-CAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juntendo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tokyo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yamaguchi University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tohoku University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyoto University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kumamoto University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Juntendo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the prevention of cardiovascular disease by moderate&#xD;
      cholesterol lowering therapy, pitavastatin 1mg/day or aggressive cholesterol lowering&#xD;
      therapy, pitavastatin 4mg/day in patients with stable coronary artery disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It was already demonstrated by previous clinical trials that statins lower the incidence of&#xD;
      death and cardiovascular events in patients with coronary artery disease. However, whether&#xD;
      aggressive cholesterol lowering therapy, using high dosage of statins, is more effective than&#xD;
      moderate cholesterol lowering therapy for the prevention of cardiovascular events in patients&#xD;
      with coronary artery disease has not been studied in Japan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2010</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of one of following events(Cardiovascular death, Non-fatal Myocardial Infarction (MI), Non-fatal Cerebral Infarction (CI), Unstable angina requiring urgent hospitalization)</measure>
    <time_frame>3-6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite cardiovascular events</measure>
    <time_frame>3-6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite coronary heart disease events</measure>
    <time_frame>3-6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite cerebrovascular events</measure>
    <time_frame>3-6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death events</measure>
    <time_frame>3-6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart disease events</measure>
    <time_frame>3-6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular events</measure>
    <time_frame>3-6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The other events</measure>
    <time_frame>3-6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13054</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Pitavastatin 1 mg daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pitavastatin 4 mg daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin 1 mg daily or 4 mg daily</intervention_name>
    <description>Patients who met all inclusion criteria and did not meet exclusion criteria (1) are entered in run-in period, loading pitavastatin 1 mg/day for more than 1 month when informed consent was given. (Primary registration) After 1 month, patients who did not meet exclusion criteria(2) are randomized to take pitavastatin 1 mg/day or 4 mg/day.</description>
    <arm_group_label>Pitavastatin 1 mg daily</arm_group_label>
    <arm_group_label>Pitavastatin 4 mg daily</arm_group_label>
    <other_name>LIVALO Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who met following all criteria are entered in run-in period, loading&#xD;
             pitavastatin 1 mg/day for more than 1 month when informed consent was given. (Primary&#xD;
             registration)&#xD;
&#xD;
          -  Coronary artery disease patients meeting one of the following events&#xD;
&#xD;
               -  History of Acute Coronary Syndrome (AMI or Unstable angina)&#xD;
&#xD;
               -  History of revascularization (PCI or CABG)&#xD;
&#xD;
               -  Diagnosis of ischemic heart disease and coronary artery stenosis as having 75% or&#xD;
                  higher stenosis according to the AHA classification&#xD;
&#xD;
          -  Hypercholesterolemia patients meeting one of following criteria&#xD;
&#xD;
               -  LDL-C is 140 mg/dL or over&#xD;
&#xD;
               -  LDL-C is 100 mg/dL or over and requiring cholesterol lowering drugs judged by&#xD;
                  attending physicians&#xD;
&#xD;
               -  Patents receiving cholesterol lowering drugs&#xD;
&#xD;
          -  Age (â‰§20 &lt;80 year-old)&#xD;
&#xD;
          -  Patients given written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion Criteria(Pre-Run-in period)&#xD;
&#xD;
          -  Patients planning revascularization&#xD;
&#xD;
          -  Malignant tumor in active phase&#xD;
&#xD;
          -  Patients who meet contraindication of LIVALO tablet below&#xD;
&#xD;
               -  Patients who have hypersensitivity to LIVALO tablet&#xD;
&#xD;
               -  Patients who have severe liver dysfunction or biliary atresia&#xD;
&#xD;
               -  Patients who are being treated with cyclosporine&#xD;
&#xD;
               -  Pregnant women, women suspected of being pregnant, or lactating women&#xD;
&#xD;
          -  Patients who have heart failure NYHA III or greater&#xD;
&#xD;
          -  Patients undergoing dialysis&#xD;
&#xD;
          -  Patients with familial hypercholesterolemia&#xD;
&#xD;
          -  Patients registered in the other clinical trials&#xD;
&#xD;
          -  Patients taking prohibited drugs&#xD;
&#xD;
          -  Patients who are ineligible in the opinion of the investigator&#xD;
&#xD;
        Exclusion Criteria(Post-Run-in period)&#xD;
&#xD;
          -  LDL-C is 120mg/dL or over after Run-in period&#xD;
&#xD;
          -  Patients with occurrence of acute coronary syndrome (AMI or Unstable angina) within 3&#xD;
             months&#xD;
&#xD;
          -  Patients who have been undergone PCI or CABG within 3 months&#xD;
&#xD;
          -  Compliance is less than 50% in Run-in period&#xD;
&#xD;
          -  Patients who met primary endpoint in Run-in period.&#xD;
&#xD;
          -  Patients who met adverse events in Run-in period and judged as ineligible in the&#xD;
             opinion of the investigator&#xD;
&#xD;
          -  Patients who are ineligible in the opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryozo Nagai, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Masunori Matsuzaki, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University School of Medicine</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 5, 2010</study_first_submitted>
  <study_first_submitted_qc>January 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2010</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pitavastatin</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

